Chongqing Claruvis Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could loosen stiff arms after stroke Results expected Sep 2026 (estimated)
- New shot could ease stiff arms for stroke survivors Results expected Jun 2027 (estimated)
-
New botulinum toxin aims to smooth frown lines in phase 2 trial
Symptom relief CompletedThis study tests a new injection called YY003, a recombinant botulinum neurotoxin type A, for treating moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Participants receive a single set of small injections into five points between the brows. The tr…
Phase 2 • Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New Botox-Like injection aims to smooth frown lines safely
Symptom relief CompletedThis study tests a new form of botulinum toxin (YY001) for treating moderate to severe frown lines between the eyebrows. About 488 adults aged 18 to 65 will receive repeated injections over time. Researchers will monitor safety, side effects, and how well the treatment works to r…
Phase 3 • Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC